Trial Profile
Phase 2a, Double-blind, Placebo-controlled, 2-period, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients With Inherited Erythromelalgia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2012
Price :
$35
*
At a glance
- Drugs Funapide (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 28 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 19 May 2010 Planned end date changed from 1 Aug 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.